PINK1 loss-of-function prevents Parkin recruitment to damaged mitochondria, blocking mitophagy. Urolithin A is proposed as a mitochondrial-targeted activator. Major limitations include urolithin A's lack of specificity for the PINK1/Parkin pathway (induces general autophagy via PGC-1α/AMPK/Nrf2), failure of PINK1 knockout mice to recapitulate human PD phenotype, and uncertain applicability to idiopathic PD when PINK1/PRKN mutations cause only ~2-3% of cases.
Curated pathway from expert analysis
flowchart TD
A["PINK1<br/>Serine/Threonine Kinase"]
B["PRKN (Parkin)<br/>E3 Ubiquitin Ligase"]
C["Mitochondrial<br/>Membrane Depolarization"]
D["PINK1<br/>Accumulation"]
E["Parkin<br/>Recruitment"]
F["Mitophagy<br/>Receptor"]
G["Dopaminergic<br/>Neuron Survival"]
H["PD<br/>Pathogenesis"]
A --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for PINK1/PRKN from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PINK1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF Urolithin A (10 μM, 24-72h) requires the PINK1/Parkin pathway to exert neuroprotective effects, THEN PINK1 knockout SH-SY5Y cells treated with urolithin A will show no significant reduction in Mito | PINK1 knockout cells will retain ≥90% baseline mitochondrial ROS levels and caspase-3 activity after urolithin A treatment, while wild-type cells will show ≥40% | — no observation — | pending | 0.35 |
| IF urolithin A's neuroprotective effects generalize beyond PINK1/PRKN mutation carriers, THEN in an idiopathic Parkinson's disease (non-familial) iPSC-derived neuron model, chronic urolithin A treatme | Idiopathic PD neurons treated with urolithin A will show ≥30% reduction in phospho-α-synuclein (Ser129) fluorescence intensity and ≥25% improvement in mitochond | — no observation — | pending | 0.25 |